Voluntary nationwide recall: Potassium (Bluepoint – June)

Aug. 2024Pharmacy Updates

BluePoint Laboratories is recalling 21 batches of Potassium Chloride Extended-Release Capsules, USP (750 mg) 10 mEq K. Potassium Chloride is used for the treatment of low potassium.

This drug is being recalled because the product failed to dissolve in the body. This may cause high potassium levels, which can result in irregular heartbeat that can lead to cardiac arrest.

As of the date of BluePoint’s recall announcement, June 25, 2024, there have been no reports of adverse events related to this recall. Consult your health care provider before you stop using this product. To see if your medication was recalled, contact your doctor or pharmacy where you received the medication or visit the FDA website below.

To learn more about this recall, you can take one or more of the steps below.

  • Talk to your doctor or pharmacist.
  • Call Sedgwick at 1-855-695-8564. TTY users should call 711. Help is available Monday through Friday from 8 a.m. to 5 p.m. EST.
  • Visit the FDA website.

Recent Announcements

The importance of PRD forms for complex patients and staying updated on changes

Personal representative designation (PRD) forms are critical to the care process for patients and providers alike. Not only do PRDs support accurate, efficient, and compliant patient care—they also streamline administrative processes.
Aug. 2025Important Notices

Important announcement: UPMC Health Plan retires MP.PA.147

This communication is in regards to UPMC Health Plan Policy MP.PA.147 – Diagnostic and Surveillance Colonoscopy, 18 Years Old and Older. UPMC Health Plan previously communicated that the prior authorization requirement under this policy would be paused until Sept. 1, 2025. However, policy MP.PA.147 has been retired, and this policy will no longer be implemented or active.
Aug. 2025Important Notices

CMS expands Medicare Advantage RADV audits to all eligible plans

On May 21, 2025, the Centers for Medicare & Medicaid Services (CMS) announced a substantial expansion of its Risk Adjustment Data Validation (RADV) audit program for Medicare Advantage plans.
Aug. 2025What's New